NCT06740526: An ongoing trial by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial is ongoing. It must report results 4 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06740526 |
|---|---|
| Title | A Phase 2b, Multicenter, Open-label, Single-arm Trial to Evaluate the Impact of Sibeprenlimab on Kidney Histopathology Through Repeat Kidney Biopsies in Adolescents and Adults With Immunoglobulin A Nephropathy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 19, 2024 |
| Completion date | April 17, 2029 |
| Required reporting date | April 17, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |